(With Adobe DRM, readable with Adobe Digital Editions for PCs and Macs, and on most mobile devices except Kindle)
Nuclear Medicine has greatly contributed to the diagnosis and treament of neuroendocrine neoplasms. This issue of PET Clinics will focus not only on the diagnosis and treatment of neuroendocrine tumors, but also theranostics. Topics include SPECT and other PET tracers, F-DOPA, Ga-DOTA-peptides, Yttrium- and Lutetium-based therapy, and the role of FDG PET. It also covers key information of theranostics.
By Stefano Fanti, Intitute of Nuclear Medicine, University of Bologna, Italy; Cristina Nanni, MD, Intitute of Nuclear Medicine, University of Bologna, Italy and Richard Baum, MD, Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Germany
Elsevier is a leading publisher of health science books and journals, helping to advance medicine by delivering superior education, reference information and decision support tools to doctors, nurses, health practitioners and students. With titles available across a variety of media—print, online and mobile, we are able to supply the information you need in the most convenient format.